Yükleniyor... / Loading...
This study investigates new biomarkers, measured from blood samples, that could predict radiation hypersensitivity in patients who will receive radiotherapy for breast cancer. It includes patients over 18 who are suitable for adjuvant radiotherapy for invasive or in situ breast cancer. It is a non-phase study that is active, not recruiting.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Patients suitable for adjuvant radiotherapy for cancer of the breast (invasive or in situ) including breast patients receiving neo-adjuvant chemotherapy. Patients receiving chemotherapy should have completed their course of chemotherapy (anthracyclines) at least one month prior to radiotherapy commencing. * No other malignancy prior to treatment for the specified tumour types except basal cell or squamous cell carcinoma of the skin * No evidence of distant metastases * Patients able to provide a venous blood sample * Willingness and ability to comply with scheduled visits, treatment plans and available for follow up * Greater than 18 years of age; no upper age limit * The capacity to understand the patient information sheet and the ability to provide written informed consent * Patients must be affiliated to a Social Security System Exclusion Criteria: * Patients with metastatic disease * Prior irradiation at the same site * Planned use of protons * Breast patients receiving concomitant chemo-radiation * Male breast cancer patients * Mastectomy patients * Bilateral breast cancer * Mental disability or patient otherwise unable to give informed consent * Limited life expectancy due to co-morbidity * Pregnant patients * Partial breast irradiation * Patients with breast implants if not removed during surgery